The observed impact on degradative pathways such as autophagy and activation of neuroprotective factors such as HSF-1, BDNF, and Sirt1 among others, make GSK-3 inhibition a particularly attractive modality for treating HD, even though only one study has used a GSK-3 inhibitor in an in vivo HD model. This evidence concerns the gene SIRT1 and Huntington disease.